Published in J Control Release on February 20, 2006
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano (2012) 1.86
Matrix metalloproteases: underutilized targets for drug delivery. J Drug Target (2007) 1.21
Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm (2008) 1.17
Effects of molecular weight and loading on matrix metalloproteinase-2 mediated release from poly(ethylene glycol) diacrylate hydrogels. AAPS J (2012) 1.12
Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release (2011) 1.09
Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.02
Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. Int J Nanomedicine (2012) 0.97
Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int J Nanomedicine (2012) 0.96
The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol (2010) 0.96
Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release (2014) 0.93
Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. J Am Chem Soc (2008) 0.91
Stimulus-responsive nanopreparations for tumor targeting. Integr Biol (Camb) (2013) 0.91
Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(ɛ-caprolactone) nanoparticles. Int J Nanomedicine (2012) 0.90
Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles. Pharm Res (2013) 0.88
Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. J Histochem Cytochem (2013) 0.83
Click chemistry in peptide-based drug design. Molecules (2013) 0.82
Enzyme-responsive nanomaterials for controlled drug delivery. Nanoscale (2014) 0.80
Improving matrix metalloproteinase-2 specific response of a hydrogel system using electrophoresis. Int J Pharm (2012) 0.80
Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA. J RNAi Gene Silencing (2014) 0.79
Advances in biomimetic regeneration of elastic matrix structures. Drug Deliv Transl Res (2012) 0.78
Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid. AAPS PharmSciTech (2010) 0.77
Galactosylated poly-L-lysine targeted microbubbles for ultrasound mediated antisense c-myc gene transfection in hepatocellular carcinoma cells. Arch Med Sci (2015) 0.76
Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment. Oncotarget (2015) 0.75
Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cells. Int J Nanomedicine (2015) 0.75
Synthesis and evaluation of L-arabinose-based cationic glycolipids as effective vectors for pDNA and siRNA in vitro. PLoS One (2017) 0.75
Luminescent proteins for high-speed single-cell and whole-body imaging. Nat Commun (2012) 2.24
piggyBac transposon-mediated long-term gene expression in mice. Mol Ther (2010) 1.33
Levels and concentration ratios of polychlorinated biphenyls and polybrominated diphenyl ethers in serum and breast milk in Japanese mothers. Environ Health Perspect (2006) 1.14
Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs (2010) 1.14
Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J Pharm Sci (2008) 1.13
Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet (2007) 1.10
Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv Drug Deliv Rev (2009) 1.07
Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials (2006) 1.07
Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice. J Pharmacol Exp Ther (2006) 1.03
Molecular weight-dependent gene transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver. Mol Ther (2003) 1.01
PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J Control Release (2006) 0.99
Creation of pure nanodrugs and their anticancer properties. Angew Chem Int Ed Engl (2012) 0.99
Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull (2002) 0.96
PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic Biol Med (2006) 0.96
Renal press-mediated transfection method for plasmid DNA and siRNA to the kidney. Biochem Biophys Res Commun (2008) 0.96
Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes. Biochem Biophys Res Commun (2002) 0.96
Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J Control Release (2007) 0.95
Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. Clin Exp Metastasis (2004) 0.95
Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. Expert Opin Drug Deliv (2006) 0.93
Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages. J Control Release (2006) 0.93
Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev (2012) 0.93
Lipid carrier systems for targeted drug and gene delivery. Chem Pharm Bull (Tokyo) (2005) 0.92
Development of polyethylene glycol-conjugated poly-S-nitrosated serum albumin, a novel S-Nitrosothiol for prolonged delivery of nitric oxide in the blood circulation in vivo. J Pharmacol Exp Ther (2005) 0.92
Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. Int J Pharm (2006) 0.91
Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of catalase. J Control Release (2009) 0.91
Efficient gene transfection by histidine-modified chitosan through enhancement of endosomal escape. Bioconjug Chem (2010) 0.91
Prevention of hepatic ischemia/reperfusion injury by prolonged delivery of nitric oxide to the circulating blood in mice. Transplantation (2008) 0.91
Gamma-polyglutamic acid-coated vectors for effective and safe gene therapy. J Control Release (2009) 0.91
Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer in human hepatoma HepG2 cells. J Control Release (2006) 0.90
Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. Int J Cancer (2002) 0.89
Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model. Mol Pharmacol (2008) 0.88
Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Ther (2003) 0.88
Factors affecting drug and gene delivery: effects of interaction with blood components. Crit Rev Ther Drug Carrier Syst (2002) 0.88
Mechanistic and empirical modeling of skin permeation of drugs. Adv Drug Deliv Rev (2003) 0.88
Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes. J Pharm Sci (2005) 0.88
Intravenous fate of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. Eur J Pharm Sci (2003) 0.88
Enhanced transfection efficiency into macrophages and dendritic cells by a combination method using mannosylated lipoplexes and bubble liposomes with ultrasound exposure. Hum Gene Ther (2010) 0.88
Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J Control Release (2006) 0.88
SOD derivatives prevent metastatic tumor growth aggravated by tumor removal. Clin Exp Metastasis (2008) 0.87
Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice. J Control Release (2009) 0.87
Prevention of ischemia/reperfusion injury by hepatic targeting of nitric oxide in mice. J Control Release (2009) 0.87
Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials (2010) 0.87
Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J Control Release (2005) 0.87
Encapsulation of the synthetic retinoids Am80 and LE540 into polymeric micelles and the retinoids' release control. J Control Release (2009) 0.87
Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors. J Pharmacol Exp Ther (2002) 0.87
Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition. Pharm Res (2002) 0.86
Determination of matrine in rat plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. Talanta (2003) 0.86
Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. Int J Pharm (2005) 0.86
Efficient gene transfer into macrophages and dendritic cells by in vivo gene delivery with mannosylated lipoplex via the intraperitoneal route. J Pharmacol Exp Ther (2006) 0.86
Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes. J Control Release (2005) 0.86
Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor. J Control Release (2004) 0.86
In silico approaches for predicting ADME properties of drugs. Drug Metab Pharmacokinet (2004) 0.86